Pharmafile Logo

The science is shifting in oncology: Are you ready to evolve with it?

August 19, 2025 | Inizio, oncology 

- PMLiVE

Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke.

This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic breast cancer introduced a ground-breaking endpoint – patients progression-free at four years – challenging long-held assumptions.

Key themes included the rise of CAR-T therapies in solid tumors, the dominance of ADCs, and the expanding role of biomarkers in driving precision medicine. Emerging tools like AI-powered biomarker detection and ctDNA for real-time monitoring are reshaping how sequencing, resistance, and adaptive treatments are approached.

Beyond the science, ASCO® 2025 underscored a new strategic imperative: it’s no longer enough to track progress – we must rethink how we plan, communicate, and act on these advances.

Read Patty’s full article here. Watch Inizio’s webinar recap Beyond the booth: Big ideas, smart spaces & strategic insights from ASCO® 2025 on demand for the full breakdown.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

5 takeaways from Reuters’ Pharma USA 2026 – and what they mean for you

Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercialization™. Now we’re back in the...

Precision Medical Affairs in Action: Using AI and Analytics to Elevate Strategy, Engagement, and Impact

Discover how AI, analytics and real-world data are reshaping Medical Affairs.

How did multifaceted support from across Inizio help a biotech firm prepare for launch?

Discover how teams from across Inizio provided a range of integrated services to give a client's product the best chance of launch success.

Our key takeaways from ISMPP EU 2026 – Evolving with Purpose: Excellence in an Era of Efficiency

Explore Inizio Medical's key takeaway from ISMPP EU 2026, including AI governance, transparency, patient partnership and evolving impact measurement.

Intelligent field team engagement: Turning shared knowledge into deeper insights and better decisions.

At Age of AI 2026, Inizio Medical’s Phil Wakefield and Inizio Ignite’s Tim Luxford will explore how cross-functional collaboration and AI can unlock faster, more actionable insights across medical and...

AI in practice: 4 real-world use cases in health and life sciences

Artificial Intelligence (AI) is often discussed in broad terms, with promises of transformation at scale. In practice, however, its value is realized in far more specific ways – when it...

How will AI change field training?

Learn how a next-generation approach to field training – powered by GenAI and avatar simulations and enabled through Intelligent Commercialization™ – can transform field force effectiveness by delivering scalable, always-on,...

Inizio Ignite Sparks a New Era of Connected Advisory Solutions

Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.

MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke

The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what...

Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series

Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.